

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Office of Technology Development](#)

[Learn About our Research & Treatment](#)

[Refer a Patient](#)

— — —

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Memorial Sloan Kettering maintains one of the world's most dynamic programs of [cancer research](#) — a scientific enterprise aimed at generating transformative and more-affordable treatments for people everywhere. While most of our research revolves around cancer, our scientists are developing technologies for a variety of applications, including the management of infectious diseases, immune system disorders, and neurologic conditions.

Memorial Sloan Kettering's tradition of laboratory scientists and physicians working together started more than 60 years ago, giving us a unique advantage in the pursuit of clinical translation and development. A wide range of technologies are taking shape in our labs and clinics, from novel biomarkers to targeted drugs, gene therapies, vaccines, medical devices, and more.

In 2011, [an independent study](#) rated Memorial Sloan Kettering the third most successful nonprofit organization with respect to the development of drugs and vaccines approved by the US Food and Drug Administration, after the National Institutes of Health and the ten-campus University of California system.

Commercialized Products

To date, research conducted at Memorial Sloan Kettering has produced 12 drugs that have been approved by the FDA for marketing, and one product approved by the US Department of Agriculture.

Learn about some of our most successful developments, including numerous lifesaving treatments and other broadly used products.

DANYELZA®

+

ERLEADA™: The First FDA-Approved Therapy to Treat Patients with Non-Metastatic Castration-Resistant Prostate Cancer

+

Folotyn™: The First Drug Approved for Treatment of Peripheral T Cell Lymphoma

+

Neupogen®: An Immune System–Stimulating Drug Benefiting People around the World

+

Thyrogen®

+

Proleukin®

+

Zolinza®

+

TOPO® Cloning

+

Vesanoid®

+

Ganite®

+

Trisenox®

+

Clolar®

+

Leukemia Diagnostics

+

The Diagnosis of Paraneoplastic Neurologic Syndromes

+

ONCEPT™

+

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center